Ładuje się......
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Secukinumab is a human monoclonal antibody with demonstrated efficacy for moderate to severe psoriasis; it binds to and neutralizes interleukin (IL)‐17A. The pharmacokinetic (PK) parameters of secukinumab were best described by a 2‐compartment model. Only weight was included in the final model, as o...
Zapisane w:
| Wydane w: | J Clin Pharmacol |
|---|---|
| Główni autorzy: | , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
John Wiley and Sons Inc.
2017
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5485066/ https://ncbi.nlm.nih.gov/pubmed/28273356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.876 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|